関連ニュース

Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and d

Alnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with tw

RADNOR, Pa., Aug. 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the feder

RADNOR, Pa., Aug. 16, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the feder

LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of in

NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). The

I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with